Additionally, Cherkassky previously demonstrated the synergistic effects of combining anti-MSLN-CAR-T cells with anti-PD-1 antibody, leading to enhanced CAR-T cell anti-tumor ability, which holds promise for extending patient survival [49]. Here, MSLN is linked to neoplasm.